A New Oral Treatment for Feline Diabetes: How SGLT2 Inhibitors Help Cats with feline diabetes

What is it about?

Feline diabetes is one of the most common hormonal diseases seen in veterinary practice. Traditionally, insulin injections have been the only treatment option, but these can be stressful for both cats and owners. Recently, a new class of oral medications called SGLT2 inhibitors, already used successfully in human medicine, has been approved for diabetic cats. These drugs help remove excess glucose through the kidneys, lowering blood sugar levels and easing the burden on the pancreas. Research shows that drugs like bexagliflozin and velagliflozin can safely control diabetes in many cats, sometimes even leading to remission. They are easy to give once daily, without the strict injection schedules required for insulin. Mild digestive upsets such as soft stools or vomiting are the most common side effects, but serious complications are rare if cats are carefully monitored during the first two weeks of treatment. This article explains how these drugs work, the evidence behind their use, and how veterinary nurses can support safe case selection, owner education, and monitoring.

Featured Image

Photo by River Kao on Unsplash

Photo by River Kao on Unsplash

Why is it important?

SGLT2 inhibitors represent the first major advance in feline diabetes treatment in over 30 years. They can reduce the need for insulin injections, improving owner compliance and strengthening the human–animal bond. Early evidence suggests similar or even higher remission rates compared to insulin therapy, making these drugs an exciting development in veterinary endocrinology. By improving quality of life and simplifying diabetes management, these treatments may reduce the number of cats euthanised soon after diagnosis due to treatment challenges. The paper provides an up-to-date, evidence-based summary for veterinary nurses and clinicians to integrate this new option safely and effectively into practice.

Perspectives